As drug companies get “really organized” about incorporating patient-centric elements in their clinical trials, a senior executive at a global courier company says the time is ripe for the EU to produce harmonized guidance on easing a clinical trial participant’s access to the study drug.
Regulators in the EU have come a long way on allowing investigational medicinal products (IMPs) to be shipped directly to clinical trial participants.
From having an “empty space” in their regulations on this topic until a few years ago, to temporarily allowing such...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
